Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Status:
RECRUITING
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).